Q-omics provides the consensus-scored UBE2E2 profile across patient tissues and cancer cell-line models. UBE2E2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, UBE2E2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, UBE2E2 protein abundance shows 17,266 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, THCA, and BRCA as cancer lineages where UBE2E2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2E2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2E2 survival associations across molecular data types. UBE2E2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2E2 RNA expression–survival associations across cancer types. High UBE2E2 expression shows unfavorable associations in MESO and BLCA, but favorable associations in LGG, CHOL, UCS and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for UBE2E2 RNA expression.
This table summarizes UBE2E2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UBE2E2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2E2 shows lower tumor expression in BLCA, UCEC, LUAD and BRCA and higher tumor expression in THCA and HNSC. The THCA box plot shows higher UBE2E2 RNA expression in tumor versus normal tissue (log2 FC = +0.765, t-test p < 0.001).
This table shows molecular features associated with UBE2E2 in patient tissues and cancer cell lines. In patient samples, UBE2E2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2E2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
